E ective in silico compound prioritization is critical to identify promising candidates in the early stages of drug discovery. Current methods typically focus on compound ranking based on one single property, for example, activity, against a single target. However, compound selectivity is also a key property that should be deliberated simultaneously so as to reduce the likelihood of undesired side e ects of future drugs. In this paper, we present a novel machinelearning based di erential compound prioritization method dCPPP. This dCPPP method learns compound prioritization models that rank active compounds well, and meanwhile, preferably rank selective compounds higher via a bi-directional push strategy. The bidirectional push is enhanced with push powers that are determined by ranking di erence of selective compounds over multiple bioassays. Our experiments demonstrate that the dCPPP achieves an overall 19.221% improvement on prioritizing selective compounds over baseline models.
INTRODUCTION
Drug discovery is time-consuming and costly: it approximately takes at least 10 to 15 years and $500 million to $2 billion to fully develop a new drug [5] . To accelerate this process, in silico methods have been extensively developed as alternatives. In silico compound prioritization, which learns computational models to rank compounds in terms of their drug-like/disease-speci c properties (e.g., e cacy, speci city), has been recently attracting increasing attention [3] . In this paper, we tackle the problem of di erential compound prioritization for better ranking selective compounds.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for pro t or commercial advantage and that copies bear this notice and the full citation on the rst page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior speci c permission and/or a fee. Request permissions from permissions@acm.org. Current compound prioritization typically focuses on one single compound property [7] , for example, biological activity. Biological activity of a compound can be initially tested in a target-speci c bioassays by measuring whether the compound binds with high a nity to the protein target that it is aimed to a ect. Activity is a critical property that a compound needs to exhibit in order to act e caciously as a successful drug. Compound prioritization in terms of activity needs to rank most active compounds on top of less active compounds.
Compound selectivity is another key property that successful drugs need to exhibit [12] . Selectivity measures how a compound can di erentially bind to only the target of interest with high a nity (i.e., high activity) while bind to other proteins with low a nities. Therefore, the compound selectivity prioritization needs to follow a combinatorial ranking criterion that 1). it ranks all the compounds well based on their activities; and meanwhile, 2). it ranks strongly selective compounds preferably higher, probably even higher than more active compounds that are not selective, in order to minimize the likelihood of undesirable side e ectss of top drug candidates [10] .
In this paper, we present an innovative machine learning method to conduct in silico compound prioritization that is able to achieve both the above goals, with a particular focus on better prioritizing selective compounds. This method consists of three components:
(1) A compound scoring function, which produces a score for each compound in a bioassay that will be used to rank the compound in the bioassay. (2) An activity ranking model, which learns the compound scoring function and approximates the ranking structure among all compounds in a bioassay. The learning is via minimizing the pairwise ordering errors introduced by the scoring function. (3) A bi-directional selectivity push strategy, which preferably pushes up selective compounds in the activity ranking model of a bioassay, and pushes down the compounds in the model that are selective in a di erent bioassay. This strategy leverages the ranking di erence of selective compounds across multiple bioassays and alters the activity ranking by pushing selectivityrelated compounds in two directions with speci c powers. These three components will be learned simultaneously within one optimization problem. This di erential Compound Prioritization via bi-directional selectivity Push with Power method is denoted as dCPPP. Figure 1 presents the overall scheme of dCPPP. To the best of our knowledge, this is the rst work in which the activity and selectivity are both tackled within one prioritization framework. 
In Silico Methods for Drug Discovery
A rst step in drug discovery is to conduct bioassays that screen a large set of promising compounds. The outcomes from bioassays inform the following drug discovery steps. Classi cation and regression dominate the in silico methods in bioassay analysis, particularly in nding the relationship between the structures of chemical compounds and their bio-chemical properties, for example, Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR). In these methods, compounds are typically represented by certain chemical ngerprints, for example, Extended Connectivity Fingerprints (ECFP) 1 . Compound activity and selectivity are used as a label/numerical target of the compounds. Popular methods include Support Vector Machines (SVM) [20] , Bayesian matrix factorization [8] , etc.
Structure-Activity-Relationship Modeling
A recent trend in SAR modeling is to leverage the information from multiple bioassays. In Ning et al. [15] , the SAR classi cation methods rst identify a set of targets related to the target of interest, and then employ various machine learning techniques (e.g., multitask learning (MTL) [4] ) to utilize activity information from these targets for a better SAR model. In Liu and Ning [13] , assistance bioassays and assistance compounds are identi ed and incorporated intelligently to build models that can accurately prioritize active compounds in a bioassay. In the Target-Related A nity Pro ling method [6] , the a nity pro les of compounds in a set of diverse bioassays are used as the ngerprints. These multi-assay based methods use multiple bioassays homogeneously and cannot utilize the di erential signals for selectivity prioritization.
Structure-Selectivity-Relationship Modeling
Existing SSR methods include multi-step classi cation based approaches [19] , in which compounds that are classi ed as active are further classi ed by a selectivity classi er; multi-class classi cation based approaches [21] , in which compound activity and selectivity are considered as two classes in a common multi-class classi er; 1 Scitegic Inc, http://www.scitegic.com. 
and multi-task based approaches [16] , which incorporates both activity and selectivity models into one model to better di erentiate activity and selectivity; etc. However, these methods cannot prioritize activity and selectivity simultaneously, or cannot leverage the prioritization structures among multiple bioassays to improve SSR modeling.
Learning to Rank
Learning to rank (LETOR) focuses on developing ranking models via learning, and has achieved tremendous success in information retrieval [14] . Existing LETOR methods fall into three categories: 1). pointwise methods, which learn individual scores that are used later for sorting; 2). pairwise methods, which model pairwise ranking relations; and 3). listwise methods, which model the full combinatorial structures of ranking lists [14] . A recent focus on LETOR is to improve the ranking performance on top of the ranking lists [1] .
The idea of using LETOR approaches to prioritize compounds has also drawn some recent attention. For example, Agarwal et al. [2] developed bipartite ranking to well-separate active compounds from inactive ones in the ranking lists. However, LETOR for compound selectivity prioritization is still less developed.
DEFINITIONS AND NOTATIONS
A compound c is active in a bioassay B with protein target t if the IC 50 2 value of c for t is less than 1 µM. A compound c is selective in a bioassay B with protein target t if the following two conditions are satis ed [16] : 1). c is active for t; and 2). min ∀t k t
IC 50 (c,t ) ≥ 50. In this paper, each bioassay has only one single protein target. Thus, activity/selectivity with respect to the bioassay and the target will be used interchangeably. A compound can be selective in at most one bioassay. A compound that is non-selective in a bioassay B k but selective in another bioassay B l is referred to as x-selective in B k . Table 1 lists the notations that are used in this paper.
METHODS 4.1 Compound Scoring
In dCPPP, the compound prioritization uses a linear scoring function as follows,s
where w is a weight vector, x i is the feature vector of the compound c i , ands i is the score over compound c i . Each compound in a bioassay is rst scored using their features, and then ranked in a non-ascending order of their scores.
Activity Prioritization
The dCPPP method will produce a ranking of compounds in a bioassay that ranks compounds well based on their activities. That is, in general, active compounds will be ranked higher than less active ones. To quantitatively measure the activity ranking quality, we use a metric non-Concordance Index (denoted as nCI) as follows,
where indicates that compound c i 's predicted score is smaller than that of c j , thus c i is ranked lower than c j . Essentially, nCI represents the fraction of mis-ordered compound pairs by a certain ranking method. A lower nCI value indicates better ranking performance. Therefore, activity prioritization seeks a scoring function that can produce low nCI, and thus nCI over the predicted ranking is used as the loss for activity prioritization in dCPPP objective:
Bi-directional Selectivity Push with Power
To favor selective compounds in compound prioritization, two key questions need to be addressed. 1). how to enforce the selective compounds to go beyond the ordinary activity prioritization and get better ranked; and 2). how much the enforcement should be. To address the rst question, we develop the bi-directional powered push scheme, which, for a target t, pushes t's selective compounds higher, and pushes t's x-selective compounds lower in compound ranking. To address the second question, we develop a scheme to determine push powers by comparing ranking di erence of a compound in multiple bioassays.
Pushing up Selective Compounds.
To push up selective compounds, dCPPP measures the ranking positions of selective compounds using their reverse height [2] and optimizes such positions.
Reverse height of a selective compound c k + i is the number of nonselective compounds ranked above c k+ i , that is,
where R k + i is the reverse height of c k + i in B k , A k is the set of nonselective compounds in B k , and I(x ) is the indicator function. Thus, to enforce higher ranking of selective compounds, it is to minimize the reverse heights of the selective compounds.
Push-up power for a selective compound c k+ i decides how strongly c k + i should be pushed up in B k , which depends on 1). how c i is ranked in B k ; and 2). how c i is ranked in other bioassays B l 's. Intuitively, if c i is ranked high in B l (i.e., c i is very active but not selective to t l ), c i should be pushed much higher in B k and much lower in B l . This is because c i is very speci c to t k , and if c i is selected for t l , it will introduce low e cacy or side e ects. Based on such intuition, we de ne the push-up power for c k + i as follows:
where θ ↑ is a parameter, and ϕ (x, |ξ ) is a thresholding function:
In
Selectivity Loss with Powered Push-up. To di erentially push selective compounds up, we take the reverse heights of selective compounds enhanced by respective push-up powers in the dCPPP learning objective, that is,
where |S k | is the size of S k .
Pushing down x-Selective Compounds.
To push down x-selective compounds, dCPPP measures the ranking positions of such x-selective compounds using their heights and optimize such positions.
Height of an x-selective compound c k − j is the number of compounds that are ranked below c k − j , that is,
where
Push-down power for an x-selective compound c k − j determines how strongly c k − j should be pushed down in a bioassay B k . We de ne the push-down power for c k − j in B k as follows,
where θ ↓ is a parameter,r k − j /r l + j is the predicted percentile ranking of c j from
is thresholding function as de ned in Equation 6 , and ξ ↓ is the thresholding parameter. Thus, if c j is not ranked signi cantly higher in B l than in B k , the push-down power is large. Please note that c j can be selective in only one bioassay, i.e., B l . Therefore, only B l is considered when pushing down c j in B k .
x-Selectivity Loss with Powered Push-down. To di erentially push x-selective compounds down, we take the heights enhanced by their push-down powers in the dCPPP learning objective, that is, 
dCPPP Optimization Problem and Solutions
The overall optimization problem of dCPPP to learn a selectivity prioritization model (i.e., the scoring function as in Equation 1, parameterized by w), which ranks selective compounds higher and x-selective compounds lower, is formulated as follows,
where α and β are two weighting parameters (α ∈ [0, 1], β ∈ [0, 1], α + β ∈ [0, 1]). Thus, the dCPPP objective is a weighted combination of the loss on 1). activity prioritization (L k c ), 2). pushing up selective compounds (L k + s ), and 3). pushing down x-selective compounds (L k − x ). Since the indicator function is not continuous or smooth, we use the logistic loss as the surrogate function [18] :
The surrogate function is continuous, smooth and di erentiable. Thus, the loss L k in Equation 11 with the surrogate function is di erentiable, and thus we can use gradient descent methods to solve the optimization problem.
MATERIALS 5.1 Dataset
We constructed a set of bioassays from ChEMBL 3 following the protocol in Section 5.1.1 in order to have su cient bioassays and sufcient active and selective compounds in each bioassay to reliably learn models. More details of the protocol are available online 4 .
Dataset Generation.
We rst selected a set of 529 bioassays, denoted as B s bioassays are further pruned in order to have reasonable number of compounds for dCPPP learning. After the pruning, all the bioassays retain all the selectivity related information (i.e., their own selective compounds and x-selective compounds), and have at around 100 compounds (if a bioasasy has more than 100 selective/x-selective compounds, all such compounds are retained). All the remaining bioassays and their compounds are used as the nal dataset in our experiments. This set of pruned bioassays is denoted as B c s .
Dataset Description.
In the nal dataset B c s , 155 bioassays have 10 ∼ 50 selective compounds and less than 500 compounds in total. Note that if a bioassay in the nal dataset has more than 100 compounds, these compounds have to be either selective compounds or x-selective compounds. Models with powered-push will be built for the set of these 155 bioassays, denoted as B m s , and baseline models (i.e., without push) will be built for all the 529 B c bioassays (B m s ⊂ B c s ). Table 2 (the "before split" row) presents the data description for B c s and B m s .
Compound Feature Generation
We used AFGen 5 to generate ngerprints from ChEMBL compound structures. Each dimension of the ngerprints represents a compound substructure, and the binary value at each dimension represents whether the corresponding substructure is present in the corresponding compound or not. For each bioassay, we calculated the pairwise Tanimoto similarity [22] of all its compounds, represented by the ngerprints, and used each row of the Tanimoto matrix as the feature representation of the corresponding compound, following the idea in [17] . Therefore, a same compound will have di erent features in di erent bioassays. This compound feature representation is unique compared to the existing compound ngerprint representations, and generated in a way that is dependent of computational tasks.
Experimental Protocol
We split each bioassay into ve folds so that selective compounds are evenly split into the ve folds. We conducted ve-fold cross validation over the splits to evaluate the dCPPP performance. Note that once the data are split, the selectivity for any training compounds needs to be re-de ned with respect to only the training (i.e., known) compounds of the bioassays. This is because that testing compounds are hold out as unknown compounds, and thus cannot be used to de ne selectivity. Similarly, the selectivity of the testing compounds (i.e., the ground-truth for performance evaluation) is also re-de ned with respect to training data. In principle, the selectivity re-de ned after data split will be di erent from that before data split. Table 2 (the "after split" row) presents the data description after the split. After the data split, all the 155 bioassays in B m s have selective compounds in at least one testing fold. The evaluation metrics are only calculated and averaged over testing folds which include selective compounds.
Evaluation Metrics

Reciprocal Selectivity Position Index (RSPI).
Absolute ranking position is an important metric in compound prioritization. In real applications, typically, only the top few compounds will be of primary interest. Thus, we de ne a reciprocal selectivity position index, denoted as RSPI, to measure the average absolute reciprocal ranking positions of selective compounds in a ranking list:
wherep k i is the ranking position of a selective compound c i in bioassay B k predicted by a ranking model. The reciprocals are used to favor highly ranked compounds by up weighting the contribution of highly ranked selective compounds, and down weighting the contribution of lowly ranked selective compounds. Higher RSPI values indicate higher average absolute ranking positions for selective compounds and thus better performance of the ranking model.
Concordance Index (CI).
Concordance Index (CI) is a popular metric that is used to evaluate the performance of ranking algorithms [9] . CI measures the fraction of correctly ordered pairs among all possible pairs and thus it is complementary to the nCI de ned in Equation 2 , that is,
Higher CI values indicate better prediction overall (i.e., more concordant pairs are predicted correctly). In our experiments, we measure the CI values over all compounds C k in a bioassay B k . We also measure the CI values among only selective compounds S k . In this case, the CI values are speci cally denoted as CI and sCI, respectively.
EXPERIMENTAL RESULTS
In the results presented in this section, we use parameters θ ↑ = 0.5 and θ ↓ = 0.5. We tried combinations of various θ ↑ and θ ↓ values, and found that θ ↑ = 0.5 and θ ↓ = 0.5 give the best performance over all the evaluation metrics overall. The baseline model corresponds to dCPPP with (α = 0, β = 0), that is, the standard ranking model without any push. The baseline model is denoted as dCPPP 0 . If each bioassay uses its own optimal α and β values (i.e., the α and β value that together give the optimal RSPI performance for each bioassay), the corresponding optimal method is denoted as dCPPP * . We also tried SVMRank [11] with Tanimoto kernel over AFGen features, and dCPPP over AFGen features as baselines. These two methods outperform dCPPP with tanimoto-similarity compound features at most by 4% but on average 8-fold slower. Thus, we use dCPPP over tanimoto-similarity compound features in the experiments. The column "RSPI", "CI" and "sCI" have the average RSPI, CI and sCI values. The row "dCPPP 0 " has the average evaluations of dCPPP 0 . The row "dCPPP * " has the average evaluations of dCPPP * . The row "imprv (%)" has the improvement of the average dCPPP * performance over the average dCPPP 0 performance. The row "best imprv (%)"
Overall Performance
has the average best improvement of dCPPP * over dCPPP 0 on each bioassay. The row "p-value" has the p-values comparing average results of dCPPP * and dCPPP 0 . Table 3 presents overall performance comparison between the dCPPP 0 and the optimal dCPPP * methods. For each bioassay, its optimal dCPPP * is the one which yields the best RSPI value, and its dCPPP 0 is the one that has the best RSPI value (and thus not the one that has the best CI due to di erent learning rates). Table 3 shows that on average, dCPPP * outperforms dCPPP 0 on RSPI signi cantly.
The results demonstrate the superiority of the dCPPP method in prioritizing selective compounds. Figure 2 presents the results of dCPPP in terms of RSPI over various α and β values (i.e., the parameters to weight the push-up and push-down terms, respectively, in dCPPP Equation 11) . The values in these gures are the average respective evaluation metric values over all the bioassays in which both push-up for selective compounds and push-down for x-selective compounds are applied (i.e., bioassays in dataset B m s ). , that is, when both the push-up and push-down are applied, the selective compounds are most e ectively to be ranked higher in the bioassays.
Selective Compound Prioritization
In particular, when α is increased from 0 (i.e., the push-up starts to take place), the RSPI values are signi cantly increased. This demonstrates the e ectiveness of the push-up strategy in ranking selective compounds on top. However, the full-power push-up (i.e., α = 1.0 and thus no ranking performance over non-selective compounds are considered in Equation 11) does not lead to optimal performance. This indicates that the prioritization of selective compounds over non-selective compounds is structurally constrained by the ordering among both selective and non-selective compounds together, and leveraging the information from non-selective compounds and their ordering structures is bene cial in improving selective compound prioritization.
On the other hand, push-down of x-selective compounds turns out to also have e ects on prioritizing selective compounds. For example, (α = 0.4, β = 0.2) (RSPI = 0.458) increases the RSPI performance over (α = 0.4, β = 0.0) (RSPI = 0.453) in Figure 2 . This may be due to the fact that the push-down exerts extra force on altering the overall ranking structures and thus better separates selective compounds from x-selective compounds. However, an over push-down (e.g., β ≥ 0.6 with α = 0.4) does not bene t selective prioritization any more. The reason could be that an overemphasis on x-selective becomes detrimental to the overall ranking structures among both selective and non-selective compounds.
For all the bioassays, we compared their RSPI values of dCPPP with (α = 0.4, β = 0.2) with the respective values of dCPPP 0 . The paired t-tests demonstrate the signi cance of the improvement from dCPPP on dCPPP 0 (p-values 2.11 × 10 −25 ). Figure 3 and 4 present the CI values among all compounds and sCI among selective compounds over all the bioassays, respectively. In Figure 3 , as α and β increase, the CI values decrease in general. This is anticipated as increasing α and β values will induce less emphasis on overall ranking structures as in Equation 11 . However, dCPPP with (α = 0.2, β = 0.0) slightly increases CI (CI = 0.636) from dCPPP 0 (CI = 0.635). This may be due to the fact that pushing up selective compounds may a ect the ranking on other non-selective compounds and thus increase CI.
Compound Ranking
In Figure 4 , the sCI performance among only selective compounds changes relatively irregularly. Speci cally, with α ∈ [0. 4, 0.6] , the optimal parameter region in which RSPI achieves the best), sCI is even below 0.5 (random ranking). This is because the selective compounds may be pushed into discordant orders compared to the ground truth. Note that the push-up power (Equation 5) is de ned based on the di erence of percentile rankings of a compound in multiple bioassays. Therefore, di erent selective compounds may receive di erent push powers within a bioassay due to their ranking positions among others bioassays. Together with the combinatorial in uence from multiple x-selective compounds pushed-down at same time in the same bioassay, it is less likely that the selective compounds are pushed up but still in their original orders as before the push.
CONCLUSIONS
In this paper, we have developed a machine learning method dCPPP. In dCPPP, activity and selectivity prioritization are both tackled within one di erential optimization model that involves collaborative information from multiple bioassays. A bi-directional powered push strategy is implemented in dCPPP, which pushes selective compounds up and x-selective compounds down in ranking.
We have also conducted a comprehensive set of experiments and analysis on the ranking performance of dCPPP. Our experiments demonstrate that dCPPP is very e ective in prioritizing selective compounds while maintaining a good activity ranking.
